Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMC3Y8)

• Drug Name: NPC-01 Drug Info
• Synonyms: LEP pill; Low dose estrogen progestin pill (dysmenorrhea), Nobelpharma

Indication

Disease Entry	ICD 11	Status	REF
Dysmenorrhea	GA34.3	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 94141
  TTD Drug ID: DMMC3Y8

Molecule-Related Drug Atlas

Drug(s) Targeting Progesterone receptor (PGR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[2]
Desogestrel	DM27U4Y	Contraception	QA21	Approved	[3]
Ulipristal	DMBNI20	Contraception	QA21	Approved	[4]
Etonogestrel	DMKA8J4	Contraception	QA21	Approved	[5]
Megestrol	DMDH9KX	Breast cancer	2C60-2C65	Approved	[6]
Segesterone acetate; ethinyl estradiol	DMFEGB0	Contraception	QA21	Approved	[7]
Norgestimate	DMYP4XC	Acne vulgaris	ED80	Approved	[5]
Dydrogesterone	DMAKIDV	Menstrual disorder	GA20.3	Approved	[8]
Medroxyprogesterone	DMBGWPH	Solid tumour/cancer	2A00-2F9Z	Approved	[8]
Ethynodiol Diacetate	DMZM84R	Contraception	QA21	Approved	[9]

Drug(s) Targeting Estrogen receptor (ESR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[10]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[11]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[11]
Estradiol Valerate	DM8MC6O	Hormone replacement therapy	8E01	Approved	[12]
Estradiol Acetate	DM07U2A	Hormone replacement therapy	8E01	Approved	[12]
Estradiol Cypionate	DM27Z5T	Hormone replacement therapy	8E01	Approved	[12]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[13]
Raloxifene	DMDKF3M	Osteoporosis	FB83.0	Approved	[14]
Ospemifene	DMC4GEI	Dyspareunia	GA12	Approved	[15]
Toremifene	DMQYUWG	Breast cancer	2C60-2C65	Approved	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Modulator	[1]
Progesterone receptor (PGR)	TTUV8G9	PRGR_HUMAN	Agonist	[1]

References

• [1] ClinicalTrials.gov (NCT01246791) Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of lipocine.
• [3] Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40.
• [4] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [5] Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.
• [6] Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8.
• [7] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [8] Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31.
• [9] Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84.
• [10] Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86.
• [11] Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
• [15] Clinical pipeline report, company report or official report of Shionogi (2011).
• [16] Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithe... Prostate Cancer Prostatic Dis. 2009;12(4):375-81.